Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy

被引:90
作者
Tian, F
Zeitler, JA
Strachan, CJ
Saville, DJ
Gordon, KC
Rades, T
机构
[1] Univ Otago, Sch Pharm, Dunedin 9001, New Zealand
[2] Univ Otago, Dept Chem, Dunedin 9001, New Zealand
关键词
carbamazepine; polymorphism; dihydrate; kinetics; morphology; Raman spectroscopy; multivariate analysis;
D O I
10.1016/j.jpba.2005.07.030
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In an aqueous environment, polymorphic forms I-III of carbamazepine all convert to the dihydrate. This study investigated the conversion of each polymorphic form individually and of a mixture of forms III and I to the dihydrate. Two batches of form I with different crystal morphology were used. Samples were dispersed independently in water at 23 +/- 1 degrees C and recovered at various timepoints varying from 10 to 210 min. Scanning electron microscopy, X-ray powder diffraction and Raman spectroscopy were used to characterize the initial polymorphic forms and the recovered samples after 210 min. Raman spectroscopy combined with partial least squares analysis was used to generate quantitative models of binary and ternary mixtures of the different polymorphic forms with the dihydrate. On the basis of these models the conversion kinetics of the polymorphic forms I-III were characterized. First-order kinetics with an unconverted portion were used to model the data (R-2 > 0.95). The unconverted portions ranged from 16 to 51% after dispersion for 210 min. The conversion kinetics were similar between polymorphic forms with comparable crystal morphology, but differed significantly between batches of the same polymorph (form 1) with different crystal morphology. Furthermore, the conversion of forms III and I in the aqueous suspension was not influenced by the presence of the other polymorph when dispersed together. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:271 / 280
页数:10
相关论文
共 56 条
[1]   Effect of packaging and storage on the stability of carbamazepine tablets [J].
Al-Zein, H ;
Riad, LE ;
Abd-Elbary, A .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (02) :223-227
[2]  
[Anonymous], AM J HOSP PHARM
[3]   Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes [J].
Anquetil, PA ;
Brenan, CJH ;
Marcolli, C ;
Hunter, IW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (01) :149-160
[4]   Qualitative and quantitative study of polymorphic forms in drug formulations by near infrared FT-Raman spectroscopy [J].
Auer, ME ;
Griesser, UJ ;
Sawatzki, J .
JOURNAL OF MOLECULAR STRUCTURE, 2003, 661 :307-317
[5]   REDUCED BIOAVAILABILITY OF MOISTURE-EXPOSED CARBAMAZEPINE RESULTING IN STATUS EPILEPTICUS [J].
BELL, WL ;
CRAWFORD, IL ;
SHIU, GK .
EPILEPSIA, 1993, 34 (06) :1102-1104
[6]  
Bernstein J., 2002, POLYMORPHISM MOL CRY, P1
[7]   Fluorescence studies of the transformation of carbamazepine anhydrate form III to its dihydrate phase [J].
Brittain, HG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (02) :375-383
[8]   X-ray characterization of the triclinic polymorph of carbamazepine [J].
Ceolin, R ;
Toscani, S ;
Gardette, MF ;
Agafonov, VN ;
Dzyabchenko, AV ;
Bachet, B .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (09) :1062-1065
[9]   Development and validation of a direct, non-destructive quantitative method for medroxyprogesterone acetate in a pharmaceutical suspension using FT-Raman spectroscopy [J].
De Beer, TRM ;
Vergote, GJ ;
Baeyens, WRG ;
Remon, JP ;
Vervaet, C ;
Verpoort, F .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 23 (4-5) :355-362
[10]  
DUGUE J, 1991, PHARM ACTA HELV, V66, P307